ESC Premium Access

Antithrombotic therapy in atrial fibrillation 2

Event: ESC CONGRESS 2016
Topic: Atrial fibrillation (AF)
Session type: Moderated Posters
Date: 30 August 2016
Time: 10:05 - 10:55


5 presentations in this session

Validation of a Modified CHA2DS2-VASc score for stroke risk Stratification in Asian patients with qtrial fibrillation

Speaker: Doctor T. Chao (Taipei, TW)

Temporal change of anticoagulation therapy and its outcomes of Japanese atrial fibrillation patients in the real-world clinical practice: the Fushimi AF Registry.

Speaker: Doctor M. Akao (Kyoto, JP)

Hospitalization-related costs among patients with atrial fibrillation treated with the factor Xa inhibitor edoxaban vs warfarin: results from the ENGAGE AF-TIMI 48 trial

Speaker: Professor E. Magnuson (Kansas City, US)

Vitamin K antagonist control for patients with nonvalvular atrial fibrillation in Eastern and Southeastern Asia: an analysis of event rates from GARFIELD-AF

Speaker: Professor S. Goto (Isehara, JP)

Reversal strategies and outcomes of major bleeding associated with direct oral anticoagulants compared to warfarin in routine practice: interim results from a multi-centre all-comer cohort

Speaker: Mr Y. Xu (Toronto, CA)

5 speakers from this session

Doctor Tze-Fan Chao

Taipei Veterans General Hospital, Taipei (Taiwan)
3 presentations
0 follower

Doctor Masaharu Akao

Kyoto Medical Center, National Hospital Organization, Kyoto (Japan)
2 presentations
0 follower

Professor Elizabeth A Magnuson

Saint Luke's Hospital, Kansas City (United States of America)
0 follower

Professor Shinya Goto

Tokai University Hospital, Isehara (Japan)
3 presentations
0 follower

Mr Yan Xu

University of Toronto, Toronto (Canada)
0 follower

This platform is supported by

logo Novo Nordisk